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Background: New techniques in assessing oocytes and embryo quality are currently explored to improve
pregnancy and delivery rates per embryo transfer. While a better understanding of embryo quality could help
optimize the existing “in vitro fertilization” (IVF) therapy schemes, it is essential to address the economic viability
of such technologies in the healthcare setting.
Methods: An Embryo-Dx economic model was constructed to assess the cost-effectiveness of 3 different IVF
strategies from a payer’s perspective; it compares Embryo-Dx with single embryo transfer (SET) to elective single
embryo transfer (eSET) and to double embryo transfer (DET) treatment practices.
Results: The introduction of a new non-invasive embryo technology (Embryo-Dx) associated with a cost up
to €460 is cost-effective compared to eSET and DET based on the cost per live birth. The model assumed that
Embryo-Dx will improve ongoing pregnancy rate/realize an absolute improvement in live births of 9% in this case.
Conclusions: This study shows that improved embryo diagnosis combined with SET may have the potential to
reduce the cost per live birth per couple treated in IVF treatment practices. The results of this study are likely more
sensitive to changes in the ongoing pregnancy rate and consequently the live birth rate than the diagnosis costs.
The introduction of a validated Embryo-Dx technology will further support a move towards increased eSET procedures
in IVF clinical practice and vice versa.Background
Increasing the efficiency of the “in vitro fertilization” (IVF)
procedure by improving pregnancy/implantation rates
and at the same time lowering (or avoiding) the risks of
multiple gestations are the primary goals of the current
assisted reproductive technology [1]. These goals require
a substantially improved gamete/embryo testing and
selection procedure which cannot be achieved by the
traditional evaluation method based on morphological
assessment. New techniques in assessing oocytes and
embryo quality are currently explored to improve preg-
nancy and delivery rates per embryo transfer. For instance,
‘Omics’ technologies, including transcriptomics, proteo-
mics, and metabolomics have begun providing evidence
that viable oocytes/embryos possess unique molecular* Correspondence: fugelhj@web.de
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unless otherwise stated.profiles with potential biomarkers that can be used for
the developmental and/or viability selection [2]. Dynamic
assessment of embryonic development by time-lapse im-
aging based on morphological grading as well as providing
kinetic parameter presents another opportunity for opti-
mizing embryo selection. A number of new non-invasive
embryo viability diagnostic tests are under development to
allow a rapid objective ranking of a patient’s cohort of
embryos for transfer in order to improve clinical pregnancy
and delivery rates per embryo transfer, thus encouraging
greater uptake of single-embryo transfer (SET).
While a better understanding of embryo quality could
help optimize the existing therapy schemes, it is essential
to address economic viability of such technologies in the
healthcare setting. As oocyte/embryo diagnostic (Embryo-
Dx) procedures prepare to enter the market, health care
decision makers (payers) will assess whether increases
in efficacy (i.e. live births) are significant enough to
justify the additional costs of the diagnostic procedure.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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requiring additional fresh or frozen cycles it might be
possible to realize a budget neutral scenario or potentially
cost-savings.
The objective of this study was to assess the clinical
and economic outcomes associated with non-invasive
embryo diagnostics (Embry-Dx) introduction into IVF
standard treatment practices. For this purpose, the
cost-effectiveness of different IVF strategies (with and
without Embryo-Dx) has been compared from a payer’s
perspective.
Value of non-invasive embryo technologies
The current research on non-invasive oocytes and embryo
technologies comprises both morphometric and biomarker
assessments. Morphometric assessment is focused on the
automatization and standardization of current morpho-
logical grading procedures; i.e. an incubator plus a camera
providing time-lapse images of embryo. A dynamic assess-
ment of embryonic development (cleavage kinetics) using
automated time-lapse imaging systems may have the poten-
tial to improve oocytes/embryo selection [3]. Biomarker
assessment is trying to identify predictive biomarkers of
oocyte/embryo viability via gene expression profiling of
cumulus cells surrounding the oocyte, and proteomic
and metabolic approaches in embryo culture media using
quantitative real-time Polymerase Chain Reaction (PCR)-
based assays microarray technologies or mass spectrom-
etry. The development of accurate and validated tests
for embryo ranking including endometrial receptivity
may significantly improve non-invasive embryo quality
assessment. There are expectations with these new
approaches to improve on-going pregnancy rates between
5-15% (absolute increase) dependent on the methodology
[4], but all of the new approaches still need to prove
clinical utility through prospective randomized clinical
trials. Although, considerable challenges lay ahead as
effective classification systems for ranking embryos con-
tinue to be developed, there is a clear need for a reliable
and non-invasive method of embryo selection to ensure
that only embryos with the highest development potential
are chosen for transfer thus reducing the need for multiple
transfers and consequent risk of multiple births. This
would support policies on elective single embryo transfer
(eSET) in many countries (e.g. HEFAa policy in the UK).
Elective single-embryo transfer has been proposed as a
strategy to reduce the risk of multiple births, which are
associated with increased maternal and neonatal compli-
cations as well as increased costs to the health service.
However, such eSET policies can only be applied success-
fully in combination with high quality embryo selection
and good cryopreservation programs [5].
While a better understanding of embryo quality could
help optimize the existing therapy schemes, it is essentialto address economic viability of such technologies in
the healthcare setting. Given the current health care
environment and limited health care resources there is
a need to consider the opportunity cost of decisions
and to evaluate efficacy and economic consequences of
different IVF strategies with and without embryo diag-
nostics, and hence to assess Embryo-DX technology in
the health economic context. Health economic evaluations
are increasingly used to support policies on reimbursement
and pricing for new innovative healthcare technology, as
well as to evaluate and advise on its use in clinical practice
[6]. A health economic evaluation (e.g. cost-effectiveness
analysis) is defined as a comparative analysis of both the
cost and the health effects of two or more alternative
health interventions [7]. Such an analysis makes it possible
to examine whether the money that would be invested in a
new intervention for a particular condition would actually
be used efficiently. The net costs can be balanced with
the net health effects, often expressed in quality-adjusted
life-years (QALYs) and the ratio, the so called ICER (incre-




A decision analytical Markov model (Embryo-Dx model -
see Figure 1) was constructed to assess the economic
consequences of 3 different IVF strategies. The Embryo-
Dx model:
a) Compares Embryo-Dx with single embryo transfer
(Embryo-Dx/SET) to eSET and to double embryo
transfer (DET) treatment practices and
b) Considers a maximum of one fresh and one frozen
cycle in the comparison of the different strategies
regarding their costs and life birth rates.
The strategies were selected for clinical relevance. Elect-
ive single-embryo transfer has been proposed in many
health care systems as a strategy to reduce the risk of mul-
tiple births, which are associated with increased maternal
and neonatal complications as well as increased costs to
the health service. For instance, in The Netherlands the
current policy is to offer SET in good prognosis patients
(i.e. young patients with a good quality embryos). On the
other hand, the DET strategy of transferring two embryos
into the uterus is still customary in the majority of women
receiving IVF treatment, particularly in older women [9].
There have been many studies comparing the economic
consequences of SET vs DET in various health care
systems [10-12]. Also, several cost-effectiveness studies
have shown that transferring one fresh embryo and
then, if needed, using one frozen and thawed embryo
may dramatically reduce the number of twin pregnancies
Figure 1 Embryo-Dx model.
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compared to DET in good prognosis patients [13]. A
cost-effectiveness study by Fiddelers et al. [14] in The
Netherlands compared seven embryo transfer strategies
varying eSET, DET and standard treatment procedure. In
this study clinical outcomes data came from a randomized
clinical trial (RCT) performed at the University Hospital
of Maastricht (Montfoort et al. [15]) where 308 couple
were randomized between eSET and DET, irrespective of
female age and embryo quality. The cost data were based
on the Dutch healthcare system. The Embryo-DX model
uses the same data sources in The Netherlands because it
provided detailed data on cost and efficacy parameters
including treatment costs in relation to treatment success,
embryo fertilization, frozen cycles, embryo production
and pregnancy rates as well as a broad range of multiple
pregnancy and post –delivery cost. The results discussedhere are broadly applicable to other markets, however
variation in the costs may change some of the results
described here.Embryo-DX technology
Several technologies are currently being developed to
improve embryo selection with the aim of improving live
birth rates and reducing multiple pregnancy rates. For
the purposes of the analysis described here we consider
embryo diagnostic testing from a theoretical perspective.
Therefore, the efficacy improvements discussed here are
not based on any specific technology and are only used
for purpose of illustration and clinical development. From
an economic perspective we can assess the anticipated
benefits with respect to the expected costs in order to
inform decision-making.
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Treatment assumptions and probabilities
The following assumptions have been used in construct-
ing the model:
1. Patients with frozen embryos would progress to
frozen embryo transfers in the second cycle.
2. Embryo diagnostics testing would not be performed
in patients with only 1 viable embryo. This
represents approximately 9% of patients treated in
The Netherland [16].
3. The benefits of embryo diagnostics are only
observed in fresh treatment cycles. For patients
undergoing embryo diagnosis and progressing to
frozen cycles, embryo diagnosis would have no
observable benefit in frozen cycles.
4. The cost of the embryo diagnostic procedure has
been included as a fixed cost irrespective of the
number of embryos retrieved and evaluated.
5. With the introduction of Embryo-Dx it was assumed
that DET transfer policy would not be used. This
was based on expert advice that Embryo-Dx would
minimize the need for DET because of the improved
efficacy and the use of DET would further increase
risk of multiple pregnancy.
6. Improved efficacy was accounted for by adjusting
the ongoing pregnancy rate.
These assumptions have been developed in conjunction
with IVF experts (see acknowledgement). The probabil-
ities for pregnancy rates are outlined in Table 1.Technical note to Embryo-Dx probabilities
In the Embryo-Dx model the on-going pregnancy rate
for eSET and DET was 21.4% and 40.3%, respectively.
Within the model we assumed that embryo diagnostics
improved the ongoing pregnancy rate with SET, and that
this ultimately resulted in improved live birth rates.
There are several reasons why adjustments were made
to the “ongoing pregnancy” rate and not to the probability




After eSET (%) 21.4 RCT data (n = 308) Maastricht
(Montfoort et al. 2006)
After DET (%) 40.3 RCT data (n = 308) Maastricht
(Montfoort et al 2006)
After DxSET 33.4 Expert opinion
For more clinical parameter see Fiddelers et al. supplementary data;
RCT: Randomized controlled trial.pregnancy rate ensures that all upstream costs in the
model are accounted for. For instance, monitoring visits
that occur during the ongoing pregnancy have to be con-
sidered appropriately. Secondly, because the model uses a
series of probabilities, it is constrained by the numbers of
people progressing through various stages of the model.
If adjustments were made only to the end probability, it
would be constrained by the number of people in earlier
Markov stages. Therefore, much larger increases to the
end probability would have been required to achieve
the improved efficacy associated with Embryo-Dx in
the model.
Costs included in model
The cost analysis was performed from a payer perspec-
tive and included direct medical costs within the health
care sector. The costs were determined empirically for
each couple starting IVF cycle up to 6 weeks after birth.
The Embryo-Dx model included the following cost vari-
ables in the analysis: Cost of IVF treatment (hormonal
stimulation, oocyte pickup, Laboratory, embryo transfer),
costs of a singleton and twin pregnancy (complicated
and non-complicated pregnancy), costs of delivery of a
singleton and twin and costs of the period from birth
until 6 weeks after birth, for the mothers as well as the
children (see Table 2). All costs were based on data from
the Netherlands and were converted to the index year of
2013 according to the consumer price index (CPI, 2013).
Base case
The model reflects a base set of assumptions for costs and
efficacy associated with introducing embryo diagnosis into
treatment practices. The base assumption on efficacy is an
ongoing pregnancy rate of 33.4% with Embryo-Dx. This
translates into an approximate 9% improvement in the live
birth rate with Embryo-Dx. The cost of the Embryo-Dx
included in the model was €400 per test regardless of the
number of embryos that were harvested.
Model output
The model estimates several parameters useful for medical
decision-making.
Firstly, the model generates the cost per couple treated.
This does not include only the costs of fertility treatment,
but also costs associated with the proportion of people
with a live birth, costs of multiples, and associated medical
costs up to 6 weeks post-delivery. It was necessary to
incorporate a range of costs in order to reflect the advan-
tages of embryo diagnostics on cost savings associated
with multiple pregnancies. Therefore, the cost per couple
does not reflect the cost per cycle as typically described in
the literature.
Secondly, the model calculates live birth rates based on
one fresh IVF cycle and the cumulative live births
Table 2 Mean costs IVF cycle until four weeks after delivery for all 308 patients included in the study
Markov cycle Resources included in model Costs per couple1 (€) mean
IVF treatment cycle Medication 1570
Hospital care 325
Ovum pick-up (OPU) 586
Laboratory 1314
Embryo transfer 310
Hospital admission/Others (GP’s) 909
Pregnancy singleton (5-40 weeks) Complications 4605
Hospital costs: consults, ultrasound
No Complications 1522
Hospital costs: consults, ultrasound/Others
Pregnancy twin (5-40 weeks) Complications 4605
Hospital costs: consults, ultrasound
No Complications 2062
Hospital costs: consults, ultrasound/Others
Delivery singleton up to 6 weeks post delivery Hospital admission and delivery 12438
Singleton complication costs
Other health care costs
Delivery twin up to 6 weeks post delivery Hospital admission 41844
Twin complication costs
Other health care costs
1Cost per couple = unit price times volumes of use.
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limited to one fresh and one frozen because of uncertainty
regarding how embryo diagnosis would impact on treat-
ment success beyond the first cycle.
Thirdly, the model generates the “cost per live birth”
and “incremental cost-effectiveness ratio (ICER)” for the
three interventions compared. The ICER is the extra cost
for a gain in one extra live birth, when two treatments
are compared. The cost per live birth and the ICER are
common metrics in cost-effectiveness studies in assisted
reproductive technologies (ART) and are familiar to pay-
ing audiences.Results
For the base case the cost and live birth rates after a single
fresh cycle followed consecutively by one frozen cycle for
eSET, DETand Embry-Dx SETare described in the Table 3
below. The cost per live birth for Embryo-Dx SET is the
lowest compared to the other strategies. The improved
live birth rate with Embrxo-Dx is still lower than the suc-
cess rates achieved with DET after two cycles. The cost of
a new Embryo-Dx explored in the base example was €400.
The ICER of Embryo-Dx SET compared to eSET versus
DET compared to eSET is lower (€15,439 versus €25,509).
The ICER for DET versus Embryo-Dx SET is €52,674.Sensitivity analyses
Appropriate sensitivity analyses were performed to test
how sensitive the results were to changes in model param-
eter values for costs and clinical probabilities. A sensitivity
analysis is based on the modification of the basic clinical
and economic estimates of input variables over a plausible
range of values to judge the effect on study results of
alternative assumptions for the range of potential values
for uncertain variables. Sensitivity analyses have been
performed for both the cost per live birth and the ICER.Embryo-Dx success sensitivity analysis
As the benefit of embryo diagnostics are only observed
in fresh treatment cycles the variation in costs and live
birth rates are only assessed here for 1 fresh cycle of
IVF. Transitions in the cost per live birth based on varia-
tions in the live birth rates with Embryo-Dx are illustrated
in Figure 2. In this analysis the live birth rate is increased
for Embryo-Dx SET patients while live birth rates for
eSET and DET are held constant. When the ongoing
pregnancy rate for Embryo-Dx is between 0.210 – 0.225
this is the least cost-effective option. However, when
the ongoing pregnancy rate for Embryo-Dx is between
0.23 – 0.33 this option is more cost-effective than eSET.
When the ongoing pregnancy rate reaches 0.335 Embryo-
Table 3 Cumulative costs and live birth rates for one fresh and one frozen cycle transferring SET, DET and Embryo-Dx
SET (Base case)
Strategy Cost Incremental cost Live births Cost per live birth ICER vs. eS ET ICER vs Embry Dx SET
eSET €14,896 - 0.314 €47,439
Embryo-Dx SET €16,687 €1,791 0.43 €38,807 €15,439
DET €18,952 €2,265 0.473 €40,068 €25,509 €52,674
€4,056‡
‡Based on cost comparison with eSET.
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red line crosses green line).
Embryo-Dx cost sensitivity analysis
Because price is an important component that influences
reimbursement, a sensitivity analysis was conducted based
on variations in the acquisition cost for a new Embryo-
Dx. In this analysis the purchase price was varied from
€200 - €600 while the base assumption for improved
ongoing pregnancy rate with Embryo-Dx was held
constant at 33.4% as the price of the test was varied.
The analysis shows that at a price of €200 - €460 the
Embryo-Dx results in the lowest cost per live birth com-
pared to eSET and DET. From €480 - €600 the cost per
live birth with Embryo-Dx SET is lower than eSET, and
slightly higher than DET (Figure 3).
In addition, we conducted extensive one-way sensitivity
analyses on the ICER for key input parameters, which may
have an impact on the outcome of the cost-effectiveness
analysis when analysis is performed for 2 cycles. The vari-
ation of the values was based on plus and minus 20% of
the base case value. The sensitivity analyses (Table 4) showSensitivity A
Probability of pregnancy






















Figure 2 Variation in embryo diagnosis on cost per live birth.that pregnancy rate to DET, is most sensitivity clinical
parameter with ICER ranging from €35,438 to €22,235
for comparison between DET versus eSET. The cost for
embryo transfer is most sensitive economic parameter with
ICER ranging from €50,314 to €54,736 for comparison
DET versus Diagnostic eSET.
The cost for diagnostic tests is not a very sensitive
economic parameter with ICER ranging from €54,596 to
€50,454 for comparison DET versus Diagnostic eSET.
The results of the sensitivity analyses show that the
outcomes of the model are robust to the uncertainty in
the input parameters of the model. Therefore the concept,
which has been presented, is not affected by huge uncer-
tainty of the underlying model, and therefore the model
suits for the purpose of illustration of the concept.
Discussion
New techniques in assessing oocytes and embryo quality
are currently explored to improve clinical pregnancy and
delivery rates per embryo transfer. The identification
of high-quality oocytes and embryos using objective
non-invasive technologies could help optimize existingnalysis on
 after diagnostic eSET
after diagnostic eSET































Figure 3 Variation in cost of Embryo-Dx on cost per live birth.
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of single-embryo transfer. However, translating new
innovative techniques (both morphometric and biomarker
assessments) into clinical practice awaits evidence of their
clinical utility. Good - quality studies of these techniques
are needed and results need to be validated in clinical
settings to determine their potential clinical and economic
application. In addition, successful embryo implantation
will require endometrial receptivity and an adequate
bi-directional communication between the blastocyst
and endometrium [17].
The Embryo-Dx model showed that under a set of base
assumptions the introduction of Embryo-Dx exam into
IVF is cost-effective compared to eSET. Based on a price
of €400 per embryo diagnosis, the cost per live birth for
Embryo-Dx is the lowest (€38,807) compared to eSET and
DET. The ICER of Embryo-Dx SET compared to eSET is
€15,439 for an extra live birth. DET is more effective but
also more costly compared to Embryo-Dx with an ICER
around €52,000 for an extra live birth. This situation
may be different if long-term cost aspects by avoiding
of high cost multiple pregnancies triggered by DET will be
considered from a broader societal perspective. However,
it depends on payers’ willingness to pay whether such new
technologies will be applied in clinical practice. Although
no agreement exists on an appropriate ceiling ration for
one extra live birth, as opposed to the ceilings ratio for a
QALY, a ceiling ration of about €15,000 (vs eSET) for
Embryo-Dx testing in this study seems low. Also, assisted
reproductive treatments present difficulties for the QALY
approach, as the main outcome of an IVF treatment is alive birth. While QALYs are intended to capture improve-
ments in health among patients, they are not appropriate
for placing a value on additional lives which is the
intended purpose of assisted reproduction [18]. Further-
more, a comprehensive economic value assessment of
new technologies may also require a budget impact ana-
lysis (BIA) to estimate the impact of the new intervention
on short- or longer-term annual healthcare budgets.
Especially local budget holders are interested to evalu-
ate the economic impact of using such new diagnostic
testing with focus on budget impact to ensure getting
sufficient value and cost offsets.
Decision making between SET and DET depends not
only on ongoing pregnancy rates and twin pregnancy rates,
but also on several other factors such as age (prognostic
indicator), patients’ preference and the health care system
in a particular country [19]. For instance, the extent of
reimbursement/coverage of the cost of new technologies
will influence the acceptance of Embryo-Dx in many mar-
kets. Current diagnostic reimbursement policies in the
US and many EU countries do not necessarily support the
development of high-value molecular tests, as reimburse-
ment of these tests has typically been based on cost, not
on value (or potential) value [20]. Funding is restricted to
hospital/clinical budget and third party payers in these
markets are not willing to cover higher priced molecular
diagnostics outside the standard procedures /DRG’s (diag-
nostic related groups). Often, flexible innovative payment
approaches outside existing reimbursement schemes are
needed to realize the benefits of these technologies on a
case-by case basis.
Table 4 Sensitivity- analysis
Clinical probabilities Range*
p_Pregnancy_cSET (mean:0.091) Input value ICER Difference
Diagnostic_eSET versus eSET 0.073 0.109 €15,481 €15,473 €8
DET versus Diagnostic eSET €52,447 €52,603 €156
DET versus eSET €25,553 €25,465 €88
p_Pregnancy_DET (mean:0.406) Input value ICER Difference
Diagnostic_eSET versus eSET 0.323 0.4843 €15,477 €15,477 €0
DET versus Diagnostic eSET Dominated** €28,826 > €28,826
DET versus eSET €35,438 €22,235 €13,202
p_Pregnancy_eSET (mean:0.214) Input value ICER Difference
Diagnostic_eSET versus eSET 0.1714 0.2572 €17,995 €20,750 €2,755
DET versus Diagnostic eSET €39,559 €39,559 €0
DET versus eSET €24,256 €29,352 €5,096
Costs
c_diagnostic tests (mean: €400) Input value ICER Difference Input value
Diagnostic_eSET versus eSET 320 480 €14,705 €16,249 €1,544
DET versus Diagnostic eSET €54,596 €50,454 €4,142
DET versus eSET €25,509 €25,509 €0
c_IVF_Medication (mean: €1570) Input value ICER Difference
Diagnostic_eSET versus eSET €1,256 €1,884 €15,705 €15,249 €456
DET versus Diagnostic eSET €52,966 €52,085 €881
DET versus eSET €25,792 €25,220 €572
c_IVF_HospCare (mean: €325) Input value ICER Difference
Diagnostic_eSET versus eSET €260 €390 €15,524 €15,430 €94
DET versus Diagnostic eSET €52,616 €52,434 €182
DET versus eSET €25,566 €25,447 €119
c_IVF_Laboratory (mean:€1314) Input value ICER Difference
Diagnostic_eSET versus eSET €1,051 €1,577 €15,596 €15,358 €238
DET versus Diagnostic eSET €52,328 €52,723 €395
DET versus eSET €25,541 €25,478 €63
c_IVF_EmbryoTransfer (mean:310) Input value ICER Difference
Diagnostic_eSET versus eSET €248 €372 €15,522 €15,432 €90
DET versus Diagnostic eSET €50,314 €54,736 €4,422
DET versus eSET €24,943 €26,075 €1,132
*Range: probabilities: plus/minus 20% but between 0 and 1.
**Diagnostic eSET is more effective and cost saving versus DET.
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some limitations. First, with respect to the scope of the
Embryo-DX model the cost-effectiveness analysis only
covers short-term (1-year) cost and health outcomes
from a payers’ perspective not including the long-term
costs associated with children born as a result of a
multiple pregnancy. Currently, an on-going TwinSing
study (Maastricht University Medical Centre) [21] is
investigating the long-term costs and outcomes of IVF
singletons and twins and it may be interesting to apply
such a long-term perspective to an Embryo-diagnosismodel. Second, adding Embryo-Dx to current IVF treat-
ment practice will increase complexity and complicates
value assessment, including uncertainties about diagnostic
characteristics (e.g. test performance) as well as gaps in
the evidence supporting clinical utility.
Conclusion
Within the limitations of this model, the results of this
study show that improved embryo diagnosis will likely
reduce the cost per live births per couple treated in IVF
treatment practices, although this conclusion is price
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lowest (€38,807) compared to eSET and DET, offsetting
assumed diagnosis cost of €400 in this analysis and
reflecting an improved cumulative delivery rate. The
results of this study are likely more sensitive to changes
in the ongoing pregnancy rate and consequently the live
birth rate than the diagnosis costs. The introduction of a
validated Embryo-Dx technology will further support a
move towards increased eSET procedures in IVF clinical
practice and vice versa. It also may trigger healthcare
coverage and reimbursement policies addressing appro-
priate DRG’s and value-based diagnostics assessment
for assisted reproductive technologies (ART). Finally, this
assessment may outline pricing opportunities/limits for
the industry to develop certain embryo diagnostic testing
products for commercialization.
Endnote
aHEFA/UK: Human Embryology and Fertilization
Authority.
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